GCC Biosimilar Contract Manufacturing Market

ID: MRFR/Pharma/50112-HCR
200 Pages
Nidhi Mandole
Last Updated: April 06, 2026
GCC Biosimilar Contract Manufacturing Market Research Report By Product (Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins), By Production Technology (Mammalian, Non-Mammalian) and By Application (Oncology, Blood Disorders, Growth Hormonal Deficiency, Chronic and amp; Autoimmune Disorders, Rheumatoid Arthritis, Others) - Growth & Industry Forecast 2025 To 2035
GCC Biosimilar Contract Manufacturing Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)18.9%
2024 Market Size$ 193.22 Million
2025 Market Size$ 229.73 Million
2035 Market Size$ 1,297.55 Million
Key Players
Samsung Biologics
Lonza Group
Boehringer Ingelheim
Fujifilm Diosynth Biotechnologies
Catalent
Wuxi Biologics
Trends
  • Rising Demand for Cost-Effective Therapies
  • Evolving Regulatory Frameworks
  • Strategic Partnerships and Collaborations
Opportunities
  • Increasing Healthcare Expenditure
  • Regulatory Support for Biosimilars
  • Growing Prevalence of Chronic Diseases
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Security, Access Control and Robotics, BY Product (USD Million)
      1. 4.1.1 Recombinant Non-glycosylated Proteins
      2. 4.1.2 Recombinant Glycosylated Proteins
    2. 4.2 Security, Access Control and Robotics, BY Production Technology (USD Million)
      1. 4.2.1 Mammalian
      2. 4.2.2 Non-Mammalian
    3. 4.3 Security, Access Control and Robotics, BY Application (USD Million)
      1. 4.3.1 Oncology
      2. 4.3.2 Blood Disorders
      3. 4.3.3 Growth Hormonal Deficiency
      4. 4.3.4 Chronic & Autoimmune Disorders
      5. 4.3.5 Rheumatoid Arthritis
      6. 4.3.6 Others
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Security, Access Control and Robotics
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Security, Access Control and Robotics
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Samsung Biologics (KR)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Lonza Group (CH)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Boehringer Ingelheim (DE)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Fujifilm Diosynth Biotechnologies (JP)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Catalent (US)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Wuxi Biologics (CN)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Rentschler Biopharma (DE)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 KBI Biopharma (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Amgen (US)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 GCC MARKET ANALYSIS BY PRODUCT
    3. 6.3 GCC MARKET ANALYSIS BY PRODUCTION TECHNOLOGY
    4. 6.4 GCC MARKET ANALYSIS BY APPLICATION
    5. 6.5 KEY BUYING CRITERIA OF SECURITY, ACCESS CONTROL AND ROBOTICS
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF SECURITY, ACCESS CONTROL AND ROBOTICS
    8. 6.8 DRIVERS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: SECURITY, ACCESS CONTROL AND ROBOTICS
    10. 6.10 SUPPLY / VALUE CHAIN: SECURITY, ACCESS CONTROL AND ROBOTICS
    11. 6.11 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCT, 2024 (% SHARE)
    12. 6.12 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCT, 2024 TO 2035 (USD Million)
    13. 6.13 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCTION TECHNOLOGY, 2024 (% SHARE)
    14. 6.14 SECURITY, ACCESS CONTROL AND ROBOTICS, BY PRODUCTION TECHNOLOGY, 2024 TO 2035 (USD Million)
    15. 6.15 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 (% SHARE)
    16. 6.16 SECURITY, ACCESS CONTROL AND ROBOTICS, BY APPLICATION, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 GCC MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY PRODUCT, 2025-2035 (USD Million)
      2. 7.2.2 BY PRODUCTION TECHNOLOGY, 2025-2035 (USD Million)
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

GCC Biosimilar Contract Manufacturing Market Segmentation

GCC Biosimilar Contract Manufacturing Market By Product (USD Million, 2025-2035)

  • Recombinant Non-glycosylated Proteins
  • Recombinant Glycosylated Proteins

GCC Biosimilar Contract Manufacturing Market By Production Technology (USD Million, 2025-2035)

  • Mammalian
  • Non-Mammalian

GCC Biosimilar Contract Manufacturing Market By Application (USD Million, 2025-2035)

  • Oncology
  • Blood Disorders
  • Growth Hormonal Deficiency
  • Chronic & Autoimmune Disorders
  • Rheumatoid Arthritis
  • Others

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.